分级预后评估系统（GPA）能预估脑转移患者的生存期。不同患者的实际预测结果可存在很大的差异。

生存期和预测生存的因素因诊断而异。 基于患者的预后，患者护理应该个体化。

这些指标是基于11个机构的3940例患者的经验而开发的（Sperduto et al，Journal of Clinical Oncology 2012：30; 419-425）。

目前，该分级预后评估系统已通过全球许多出版物的独立验证，并且现在被用来对临床试验进行分层。

The Graded Prognostic Assessment (GPA) estimates survival for patients with brain metastases. Actual outcomes for individual patients can vary widely.

Survival and the factors that predict survival vary by diagnosis. Patient care should be individualized based on the patient's prognosis.

These indices have been developed based on the experience of 11 institutions with 3940 patients (Sperduto et al, Journal of Clinical Oncology 2012:30;419-425).

The GPA has been independently validated by numerous publications from around the world and is now used to stratify clinical trials.